These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1588862)

  • 1. A cost-effectiveness analysis of hormone replacement therapy in the menopause.
    Cheung AP; Wren BG
    Med J Aust; 1992 Mar; 156(5):312-6. PubMed ID: 1588862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy.
    Tosteson AN; Rosenthal DI; Melton LJ; Weinstein MC
    Ann Intern Med; 1990 Oct; 113(8):594-603. PubMed ID: 2119161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risks, benefits and costs of hormone replacement therapy in menopause].
    Gaspard U
    Rev Med Liege; 1998 May; 53(5):298-304. PubMed ID: 9689887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease.
    Whittington R; Faulds D
    Pharmacoeconomics; 1994 Jun; 5(6):513-54. PubMed ID: 10147266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy.
    Mullins CD; Ohsfeldt RL
    J Manag Care Pharm; 2003; 9(2):150-8. PubMed ID: 14613344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture.
    Geelhoed E; Harris A; Prince R
    Aust J Public Health; 1994 Jun; 18(2):153-60. PubMed ID: 7948331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of hormone replacement therapy after the menopause.
    Tosteson AN; Weinstein MC
    Baillieres Clin Obstet Gynaecol; 1991 Dec; 5(4):943-59. PubMed ID: 1822828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone replacement therapy in a risk-benefit perspective.
    Daly E; Vessey MP; Barlow D; Gray A; McPherson K; Roche M
    Maturitas; 1996 Mar; 23(2):247-59. PubMed ID: 8735363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An economic analysis of hormone replacement therapy for the prevention of fracture in young postmenopausal women.
    Lamy O; Krieg MA; Burckhardt P; Wasserfallen JB
    Expert Opin Pharmacother; 2003 Sep; 4(9):1479-88. PubMed ID: 12943477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen use in postmenopausal women--costs, risks, and benefits.
    Weinstein MC
    N Engl J Med; 1980 Aug; 303(6):308-16. PubMed ID: 6770270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of hormone replacement therapy in the menopause.
    Weinstein MC; Schiff I
    Obstet Gynecol Surv; 1983 Aug; 38(8):445-55. PubMed ID: 6310460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention and treatment of osteoporosis with hormone replacement therapy.
    Christiansen C
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 1():45-54. PubMed ID: 8499959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding.
    Lethaby A; Suckling J; Barlow D; Farquhar CM; Jepson RG; Roberts H
    Cochrane Database Syst Rev; 2004; (3):CD000402. PubMed ID: 15266429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone replacement therapy: I. A pharmacoeconomic appraisal of its therapeutic use in menopausal symptoms and urogenital estrogen deficiency.
    Whittington R; Faulds D
    Pharmacoeconomics; 1994 May; 5(5):419-45. PubMed ID: 10147233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial.
    Lekander I; Borgström F; Ström O; Zethraeus N; Kanis JA
    Bone; 2008 Feb; 42(2):294-306. PubMed ID: 18053789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone replacement therapy: benefit, risk and cost considerations.
    Tosteson AN
    J Clin Pharmacol; 1994 Jul; 34(7):719-22. PubMed ID: 7929865
    [No Abstract]   [Full Text] [Related]  

  • 17. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.
    Stevenson M; Davis S; Lloyd-Jones M; Beverley C
    Health Technol Assess; 2007 Feb; 11(4):1-134. PubMed ID: 17280622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding.
    Lethaby A; Farquhar C; Sarkis A; Roberts H; Jepson R; Barlow D
    Cochrane Database Syst Rev; 2000; (2):CD000402. PubMed ID: 10796715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of hormone therapy in the United States.
    Lekander I; Borgström F; Ström O; Zethraeus N; Kanis JA
    J Womens Health (Larchmt); 2009 Oct; 18(10):1669-77. PubMed ID: 19857096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of osteoporosis liaison service for secondary fracture prevention in postmenopausal osteoporosis patients with previous hip fracture in Japan.
    Moriwaki K; Noto S
    Osteoporos Int; 2017 Feb; 28(2):621-632. PubMed ID: 27699441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.